| Literature DB >> 27141977 |
Olivier Windisch1, Claudia-Paula Heidegger2, Raphaël Giraud2, Philippe Morel3, Léo Bühler3.
Abstract
This review article analyzes, through a nonsystematic approach, the pathophysiology of acute pancreatitis (AP) with a focus on the effects of thoracic epidural analgesia (TEA) on the disease. The benefit-risk balance is also discussed. AP has an overall mortality of 1 %, increasing to 30 % in its severe form. The systemic inflammation induces a strong activation of the sympathetic system, with a decrease in the blood flow supply to the gastrointestinal system that can lead to the development of pancreatic necrosis. The current treatment for severe AP is symptomatic and tries to correct the systemic inflammatory response syndrome or the multiorgan dysfunction. Besides the removal of gallstones in biliary pancreatitis, no satisfactory causal treatment exists. TEA is widely used, mainly for its analgesic effect. TEA also induces a targeted sympathectomy in the anesthetized region, which results in splanchnic vasodilatation and an improvement in local microcirculation. Increasing evidence shows benefits of TEA in animal AP: improved splanchnic and pancreatic perfusion, improved pancreatic microcirculation, reduced liver damage, and significantly reduced mortality. Until now, only few clinical studies have been performed on the use of TEA during AP with few available data regarding the effect of TEA on the splanchnic perfusion. Increasing evidence suggests that TEA is a safe procedure and could appear as a new treatment approach for human AP, based on the significant benefits observed in animal studies and safety of use for human. Further clinical studies are required to confirm the clinical benefits observed in animal studies.Entities:
Keywords: Acute pancreatitis; Microcirculation; Mortality; Pancreas necrosis; Splanchnic perfusion; Thoracic epidural analgesia/anesthesia
Mesh:
Year: 2016 PMID: 27141977 PMCID: PMC4855315 DOI: 10.1186/s13054-016-1292-7
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Animal studies focusing on the role of thoracic epidural analgesia in acute pancreatitis
| First author and reference | Year | Subjects | Number | Groups | Epidural analgesia | Main measures | Findings | Comments |
|---|---|---|---|---|---|---|---|---|
| Demirag [ | 2006 | Rats | 19 | Three groups: | Catheter positioned between T7 and T9. Bupivacaine 0.4 % 20 μl/h | Hemodynamic and biological parameters | - TEA induced a strong increase in pancreatic microcirculation compared with AP group | Three different groups Histological analysis |
| Lauer [ | 2007 | Rats | 21 | Three groups: | Catheter insertion in L3– L4, advanced to T6. Bupivacaine 0.5 % 15 μl/h | In-vivo and in-vitro analysis Hemodynamic and biological parameters | - AP group had more severe metabolic and lactate acidosis compared with rats benefitting from TEA | Three different groups In-vivo and in-vitro analysis |
| Freise [ | 2009 | Rats | 28 + 22 | Four groups: | Catheter insertion in L3– L4, advanced to T6. Bupivacaine 0.5 % 15 μl/h | Hemodynamic and biological parameters | - TEA reduced overall apoptosis and hepatocyte apoptosis compared with AP | Four different groups |
| Freise [ | 2006 | Rats | 28 | Four groups: 1) Shama + NaCl [ | Catheter insertion in L3– L4, advanced to T6. Bupivacaine 0.5 % 15 μl/h | Intravital microscopy of ileal mucosa | - TEA increased survival at 7 days from 33 to 73 % compared with AP group | 7 days of follow-up |
| Bachmann [ | 2013 | Pigs | 34 | Two groups: 1) AP + TEA [ | Catheter positioned between T7 and T8. Bupivacaine 0.5 % bolus + continuous 4 ml/h | Hemodynamic and biological parameters, arterial blood gases Laser Doppler flow measures of pancreas microcirculation | - TEA improved overall survival at 7 days, from 29 % in AP group to 82 % in the group receiving TEA | 7 days of follow-up |
aSham defines a group with no induction of acute pancreatitis
TEA thoracic epidural analgesia, AP acute pancreatitis, FasL Fas ligand, IL interleukin
Human studies focusing on the role of thoracic epidural analgesia in acute pancreatitis
| First author and reference | Year | Number | Type of study | Epidural analgesia | Measures | Findings | Strength of the study |
|---|---|---|---|---|---|---|---|
| Bernhardt [ | 2002 | 121 | Prospective observational study | Catheters were placed in the thoracolumbar region, varying from T8 to L3, most of them being placed between T10 and L1 70 % were thoracic blocks and 30 % were lumbar blocks Epidural analgesia was managed with boli of 3–5 ml of bupivacaine 0.25 % every 4–6 hours. No continuous administration | Safety of procedure | - The median epidural block length was 4.2 days | Large sample, representative of general population (mean 53.2 years, extremes 15–87) Precise follow-up of doses needed to reach sufficient analgesia |
| Jabaudon [ | 2015 | 121 | Prospective observational multicenter study | Catheters were placed in the thoracolumbar region: 89 % were thoracic blocks and 11 % were lumbar blocks Each center had its own epidural protocol: 26 % used levobupivacaine and 74 % used ropivacaine Local anesthetics were always combined with sufentanil | Safety of procedure in severe patients | - The mean epidural block length was 11 days | Large sample, but only 38 patients experiencing AP Multicenter study |
| Sadowski [ | 2015 | 35 | Randomized control trial Group 1: AP + TEA [ | All catheters were placed at the thoracic level between T6 and T9, reaching a T4–T12 sensitive block Epidural analgesia was managed on a patient-controlled protocol, with continuous infusion of bupivacaine 0.1 % + fentanyl 2 μg/ml 6–15 ml/h + boli of 3–5 ml every 30–60 min | Safety of TEA in severe AP patients | - The median epidural block length was 5.7 days | Randomized control trial Study conducted on patients experiencing severe disease Blinded radiologist |
TEA thoracic epidural analgesia, AP acute pancreatitis